Niagen Bioscience, Inc. Balance Sheet
NAGE|15 years of annual SEC 10-K data (FY2011-FY2025)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 15 fiscal years. All figures from audited SEC 10-K filings.
Niagen Bioscience, Inc. had $106M in total assets and $77M in shareholders' equity as of FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | - | - | - | - | $28.2M | $16.7M | $18.8M | - | - | - | - | - | - | - | - |
| Accounts Receivable | $9.7M | - | - | $8.5M | $5.2M | - | $2.2M | $4.4M | $5.3M | $5.9M | $2.5M | $1.9M | $838.8K | $1.9M | $723.7K |
| Inventory | - | $9.2M | $14.5M | $14.7M | $13.6M | $11.7M | $11.5M | $8.2M | $5.8M | $7.9M | $8.2M | $3.7M | $2.2M | $5.2M | $2.9M |
| Current Assets | $96.8M | $64.1M | $49.5M | $46.6M | $48.9M | $32.2M | $33.5M | $36.5M | $57.2M | $15.7M | $16.5M | $9.9M | $5.8M | $7.9M | $5.0M |
| PP&E (Net) | - | $1.7M | $2.1M | $2.8M | $3.0M | $3.2M | $3.8M | $3.6M | $2.9M | $1.8M | $1.8M | $1.3M | $1.1M | $936.4K | $1.2M |
| Total Assets | $106.4M | $68.3M | $55.0M | $54.1M | $57.8M | $38.4M | $40.2M | $42.2M | $62.7M | $19.8M | $18.7M | $11.5M | $9.0M | $9.0M | $6.3M |
| Current Liabilities | $19.9M | $17.9M | $20.6M | $17.9M | $17.6M | $16.5M | $15.1M | $14.4M | $8.1M | $8.9M | $9.6M | $5.0M | $2.8M | $4.8M | $3.3M |
| Total Debt | - | - | - | - | - | - | - | - | - | $0 | $5.0M | $2.5M | - | - | - |
| Shareholders' Equity | $76.5M | $28.5M | $28.7M | $31.7M | $16.4M | $20.4M | $20.4M | $53.8M | $53.8M | $10.0M | $5.3M | $4.0M | $4.0M | $2.6M | $4.9M |